Work with thought leaders and academic experts in oncology
Companies can greatly benefit from working with an expert in the field of Oncology. Here are a few reasons why: 1. Cutting-edge Research: Oncology experts stay updated with the latest advancements in cancer research, providing valuable insights and innovative solutions. 2. Clinical Trials: Collaborating with an Oncology researcher allows companies to conduct clinical trials, accelerating the development of new treatments and therapies. 3. Expertise in Precision Medicine: Oncology researchers specialize in personalized medicine, helping companies develop targeted therapies based on individual patient characteristics. 4. Access to Networks: Academic researchers in Oncology have extensive networks within the medical community, providing access to key opinion leaders, clinicians, and other experts. 5. Regulatory Compliance: Oncology experts are well-versed in regulatory requirements, ensuring companies meet all necessary guidelines and standards.
Experts on NotedSource with backgrounds in oncology include Dushani L. Palliyaguru, Ph.D., Ramy Ayoub, Michael W Harman, Luca Delfinis, Boris Leibovitch, Jeffrey Townsend, Athul Prasad, Liam D. Hendrikse, Ph.D., Giuliana Noratto, Marina Baretti, Abiodun Adewuya, Ramy Ayoub, Timothy Sears, Katelyn Katelyn Masiuk, Kayvan Najarian, Amir Manbachi, Jens Hegg, Olivier Saulnier, AMAN SHARMA, Mehrdad Sheikhvatan, Niko Popitsch, Sitapriya Moorthi, Jonathan Eby, and Zinaida Good.
Dushani L. Palliyaguru, Ph.D.
Toxicologist | Aging, Nutrition and Metabolism Research Scientist | Systems Biologist
Most Relevant Research Interests
Other Research Interests (20)
About
Most Relevant Publications (1+)
21 total publications
Frugal chemoprevention: targeting Nrf2 with foods rich in sulforaphane
Seminars in Oncology / Feb 01, 2016
Yang, L., Palliyaguru, D. L., & Kensler, T. W. (2016). Frugal chemoprevention: targeting Nrf2 with foods rich in sulforaphane. Seminars in Oncology, 43(1), 146–153. https://doi.org/10.1053/j.seminoncol.2015.09.013
Ramy Ayoub
PhD Candidate Medical Biophysics
Most Relevant Research Interests
Other Research Interests (17)
About
Most Relevant Publications (2+)
7 total publications
QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY
Neuro-Oncology / Jun 01, 2018
Ayoub, R., Miller, F., Beera, K., de Medeiros, C., Laughlin, S., Bouffet, E., & Mabbott, D. (2018). QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY. Neuro-Oncology, 20(suppl_2), i168–i168. https://doi.org/10.1093/neuonc/noy059.634
MEDB-78. Unified rhombic lip origins of Group 3 and Group 4 medulloblastoma
Neuro-Oncology / Jun 01, 2022
Smith, K., Bihannic, L., Gudenas, B., Gao, Q., Haldipur, P., Tao, R., Iskusnykh, I., Chizhikov, V., Scoggins, M., Zhang, S., Edwards, A., Deng, M., Glass, I., Overman, L., Millman, J., Sjoboen, A., Hadley, J., Mankad, K., Onar-Thomas, A., … Northcott, P. (2022). MEDB-78. Unified rhombic lip origins of Group 3 and Group 4 medulloblastoma. Neuro-Oncology, 24(Supplement_1), i124–i125. https://doi.org/10.1093/neuonc/noac079.452
Michael W Harman
Distinguished Subject Matter Expert & Leader in Medical Technologies.
Most Relevant Research Interests
Other Research Interests (15)
About
Most Relevant Publications (2+)
15 total publications
Abstract 3591: Expression of 14-3-3 gamma stabilizes polyploidization in NSCLC cells
Cancer Research / Jul 15, 2016
Gomes, C. J., Harman, M., Centuori, S., Wolgemuth, C., & Martinez, J. (2016). Abstract 3591: Expression of 14-3-3 gamma stabilizes polyploidization in NSCLC cells. Cancer Research, 76(14_Supplement), 3591–3591. https://doi.org/10.1158/1538-7445.am2016-3591
Abstract 2066: Aberrant upregulation of 14-3-3 gamma promotes mononucleated polyploidization in human lung cancers
Cancer Research / Aug 01, 2015
Gomes, C. J., Harman, M., Martinez, J., & Centuori, S. (2015). Abstract 2066: Aberrant upregulation of 14-3-3 gamma promotes mononucleated polyploidization in human lung cancers. Cancer Research, 75(15_Supplement), 2066–2066. https://doi.org/10.1158/1538-7445.am2015-2066
Boris Leibovitch
Experienced wet lab and in teaching Molecular Cell biologist, geneticist, cancer biologist in Academia
Most Relevant Research Interests
Other Research Interests (11)
About
Most Relevant Publications (5+)
22 total publications
Targeted interference of SIN3A-TGIF1 function by SID decoy treatment inhibits Wnt signaling and invasion in triple negative breast cancer cells
Oncotarget / Aug 19, 2016
Kwon, Y.-J., Leibovitch, B. A., Bansal, N., Pereira, L., Chung, C.-Y., Ariztia, E. V., Zelent, A., Farias, E. F., & Waxman, S. (2016). Targeted interference of SIN3A-TGIF1 function by SID decoy treatment inhibits Wnt signaling and invasion in triple negative breast cancer cells. Oncotarget, 8(51), 88421–88436. https://doi.org/10.18632/oncotarget.11381
Blocking the PAH2 domain of Sin3A inhibits tumorigenesis and confers retinoid sensitivity in triple negative breast cancer
Oncotarget / Jun 07, 2016
Bansal, N., Bosch, A., Leibovitch, B., Pereira, L., Cubedo, E., Yu, J., Pierzchalski, K., Jones, J. W., Fishel, M., Kane, M., Zelent, A., Waxman, S., & Farias, E. (2016). Blocking the PAH2 domain of Sin3A inhibits tumorigenesis and confers retinoid sensitivity in triple negative breast cancer. Oncotarget, 7(28), 43689–43702. https://doi.org/10.18632/oncotarget.9905
Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
Molecular Cancer Therapeutics / Aug 01, 2015
Kwon, Y.-J., Petrie, K., Leibovitch, B. A., Zeng, L., Mezei, M., Howell, L., Gil, V., Christova, R., Bansal, N., Yang, S., Sharma, R., Ariztia, E. V., Frankum, J., Brough, R., Sbirkov, Y., Ashworth, A., Lord, C. J., Zelent, A., Farias, E., … Waxman, S. (2015). Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 14(8), 1824–1836. https://doi.org/10.1158/1535-7163.mct-14-0980-t
Targeting the SIN3A-PF1 interaction inhibits epithelial to mesenchymal transition and maintenance of a stem cell phenotype in triple negative breast cancer
Oncotarget / Oct 09, 2015
Bansal, N., Petrie, K., Christova, R., Chung, C.-Y., Leibovitch, B. A., Howell, L., Gil, V., Sbirkov, Y., Lee, E., Wexler, J., Ariztia, E. V., Sharma, R., Zhu, J., Bernstein, E., Zhou, M.-M., Zelent, A., Farias, E., & Waxman, S. (2015). Targeting the SIN3A-PF1 interaction inhibits epithelial to mesenchymal transition and maintenance of a stem cell phenotype in triple negative breast cancer. Oncotarget, 6(33), 34087–34105. https://doi.org/10.18632/oncotarget.6048
Invasive phenotype in triple negative breast cancer is inhibited by blocking SIN3A–PF1 interaction through KLF9 mediated repression of ITGA6 and ITGB1
Translational Oncology / Feb 01, 2022
Kadamb, R., Leibovitch, B. A., Farias, E. F., Dahiya, N., Suryawanshi, H., Bansal, N., & Waxman, S. (2022). Invasive phenotype in triple negative breast cancer is inhibited by blocking SIN3A–PF1 interaction through KLF9 mediated repression of ITGA6 and ITGB1. Translational Oncology, 16, 101320. https://doi.org/10.1016/j.tranon.2021.101320
Jeffrey Townsend
Professor of Biostatistics and Ecology & Evolutionary Biology
Most Relevant Research Interests
Other Research Interests (78)
About
Most Relevant Publications (21+)
207 total publications
Estimation of Neutral Mutation Rates and Quantification of Somatic Variant Selection Using cancereffectsizeR
Cancer Research / Dec 05, 2022
Mandell, J. D., Cannataro, V. L., & Townsend, J. P. (2022). Estimation of Neutral Mutation Rates and Quantification of Somatic Variant Selection Using cancereffectsizeR. Cancer Research, 83(4), 500–505. https://doi.org/10.1158/0008-5472.can-22-1508
In Response to “De Novo KRAS G12C-Mutant SCLC: A Case Report”
JTO Clinical and Research Reports / Dec 01, 2022
Moore, M., Zhuo, Y., Mandell, J. D., Gaffney, S. G., & Townsend, J. P. (2022). In Response to “De Novo KRAS G12C-Mutant SCLC: A Case Report.” JTO Clinical and Research Reports, 3(12), 100418. https://doi.org/10.1016/j.jtocrr.2022.100418
Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia
Leukemia / Nov 11, 2022
Mandell, J. D., Fisk, J. N., Cyrenne, E., Xu, M. L., Cannataro, V. L., & Townsend, J. P. (2022). Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia. Leukemia, 36(12), 2931–2933. https://doi.org/10.1038/s41375-022-01752-5
Cancer Relevance of Human Genes
JNCI: Journal of the National Cancer Institute / Apr 13, 2022
Qing, T., Mohsen, H., Cannataro, V. L., Marczyk, M., Rozenblit, M., Foldi, J., Murray, M., Townsend, J. P., Kluger, Y., Gerstein, M., & Pusztai, L. (2022). Cancer Relevance of Human Genes. JNCI: Journal of the National Cancer Institute, 114(7), 988–995. https://doi.org/10.1093/jnci/djac068
Quarantine and testing strategies to ameliorate transmission due to travel during the COVID-19 pandemic: a modelling study
The Lancet Regional Health - Europe / Mar 01, 2022
Wells, C. R., Pandey, A., Fitzpatrick, M. C., Crystal, W. S., Singer, B. H., Moghadas, S. M., Galvani, A. P., & Townsend, J. P. (2022). Quarantine and testing strategies to ameliorate transmission due to travel during the COVID-19 pandemic: a modelling study. The Lancet Regional Health - Europe, 14, 100304. https://doi.org/10.1016/j.lanepe.2021.100304
Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma
Cancer Letters / Feb 01, 2022
Fisk, J. N., Mahal, A. R., Dornburg, A., Gaffney, S. G., Aneja, S., Contessa, J. N., Rimm, D., Yu, J. B., & Townsend, J. P. (2022). Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma. Cancer Letters, 526, 346–351. https://doi.org/10.1016/j.canlet.2021.11.011
Environmental and sex-specific molecular signatures of glioma causation
Neuro-Oncology / May 04, 2021
Claus, E. B., Cannataro, V. L., Gaffney, S. G., & Townsend, J. P. (2021). Environmental and sex-specific molecular signatures of glioma causation. Neuro-Oncology, 24(1), 29–36. https://doi.org/10.1093/neuonc/noab103
Heavy mutagenesis by tobacco leads to lung adenocarcinoma tumors with KRAS G12 mutations other than G12D, leading KRAS G12D tumors—on average—to exhibit a lower mutation burden
Lung Cancer / Apr 01, 2022
Tan, C., Mandell, J. D., Dasari, K., Cannataro, V. L., Alfaro-Murillo, J. A., & Townsend, J. P. (2022). Heavy mutagenesis by tobacco leads to lung adenocarcinoma tumors with KRAS G12 mutations other than G12D, leading KRAS G12D tumors—on average—to exhibit a lower mutation burden. Lung Cancer, 166, 265–269. https://doi.org/10.1016/j.lungcan.2021.10.008
Non-Coding Mutations in Urothelial Bladder Cancer: Biological and Clinical Relevance and Potential Utility as Biomarkers
Bladder Cancer / Jun 11, 2020
Yang, A., Cross, C. N., & Townsend, J. P. (2020). Non-Coding Mutations in Urothelial Bladder Cancer: Biological and Clinical Relevance and Potential Utility as Biomarkers. Bladder Cancer, 6(2), 211–213. https://doi.org/10.3233/blc-200278
Transfer RNA methyltransferase gene NSUN2 mRNA expression modifies the effect of T cell activation score on patient survival in head and neck squamous carcinoma
Oral Oncology / Feb 01, 2020
Lu, L., Gaffney, S. G., Cannataro, V. L., & Townsend, J. (2020). Transfer RNA methyltransferase gene NSUN2 mRNA expression modifies the effect of T cell activation score on patient survival in head and neck squamous carcinoma. Oral Oncology, 101, 104554. https://doi.org/10.1016/j.oraloncology.2019.104554
The landscape of novel and complementary targets for immunotherapy: an analysis of gene expression in the tumor microenvironment
Oncotarget / Jul 16, 2019
Gaffney, S. G., Perry, E. B., Chen, P.-M., Greenstein, A., Kaech, S. M., & Townsend, J. P. (2019). The landscape of novel and complementary targets for immunotherapy: an analysis of gene expression in the tumor microenvironment. Oncotarget, 10(44), 4532–4545. https://doi.org/10.18632/oncotarget.27027
Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck
Clinical Cancer Research / Jun 01, 2019
Lee, J. W., Parameswaran, J., Sandoval-Schaefer, T., Eoh, K. J., Yang, D., Zhu, F., Mehra, R., Sharma, R., Gaffney, S. G., Perry, E. B., Townsend, J. P., Serebriiskii, I. G., Golemis, E. A., Issaeva, N., Yarbrough, W. G., Koo, J. S., & Burtness, B. (2019). Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 25(11), 3430–3442. https://doi.org/10.1158/1078-0432.ccr-18-0440
Somatic evolutionary timings of driver mutations
BMC Cancer / Jan 18, 2018
Gomez, K., Miura, S., Huuki, L. A., Spell, B. S., Townsend, J. P., & Kumar, S. (2018). Somatic evolutionary timings of driver mutations. BMC Cancer, 18(1). https://doi.org/10.1186/s12885-017-3977-y
Effect Sizes of Somatic Mutations in Cancer
JNCI: Journal of the National Cancer Institute / Oct 26, 2018
Cannataro, V. L., Gaffney, S. G., & Townsend, J. P. (2018). Effect Sizes of Somatic Mutations in Cancer. JNCI: Journal of the National Cancer Institute, 110(11), 1171–1177. https://doi.org/10.1093/jnci/djy168
Analysis of mutation, selection, and epistasis: an informed approach to cancer clinical trials
Oncotarget / Apr 27, 2018
Wilkins, J. F., Cannataro, V. L., Shuch, B., & Townsend, J. P. (2018). Analysis of mutation, selection, and epistasis: an informed approach to cancer clinical trials. Oncotarget, 9(32), 22243–22253. https://doi.org/10.18632/oncotarget.25155
CDKN2A Copy Number Loss Is an Independent Prognostic Factor in HPV-Negative Head and Neck Squamous Cell Carcinoma
Frontiers in Oncology / Apr 04, 2018
Chen, W. S., Bindra, R. S., Mo, A., Hayman, T., Husain, Z., Contessa, J. N., Gaffney, S. G., Townsend, J. P., & Yu, J. B. (2018). CDKN2A Copy Number Loss Is an Independent Prognostic Factor in HPV-Negative Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology, 8. https://doi.org/10.3389/fonc.2018.00095
PhyloOncology: Understanding cancer through phylogenetic analysis
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer / Apr 01, 2017
Somarelli, J. A., Ware, K. E., Kostadinov, R., Robinson, J. M., Amri, H., Abu-Asab, M., Fourie, N., Diogo, R., Swofford, D., & Townsend, J. P. (2017). PhyloOncology: Understanding cancer through phylogenetic analysis. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1867(2), 101–108. https://doi.org/10.1016/j.bbcan.2016.10.006
Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function
Annals of Oncology / Jan 01, 2017
Choi, M., Kadara, H., Zhang, J., Parra, E. R., Rodriguez-Canales, J., Gaffney, S. G., Zhao, Z., Behrens, C., Fujimoto, J., Chow, C., Kim, K., Kalhor, N., Moran, C., Rimm, D., Swisher, S., Gibbons, D. L., Heymach, J., Kaftan, E., Townsend, J. P., … Wistuba, I. I. (2017). Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Annals of Oncology, 28(1), 83–89. https://doi.org/10.1093/annonc/mdw437
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up
Annals of Oncology / Jan 01, 2017
Kadara, H., Choi, M., Zhang, J., Parra, E. R., Rodriguez-Canales, J., Gaffney, S. G., Zhao, Z., Behrens, C., Fujimoto, J., Chow, C., Yoo, Y., Kalhor, N., Moran, C., Rimm, D., Swisher, S., Gibbons, D. L., Heymach, J., Kaftan, E., Townsend, J. P., … Herbst, R. S. (2017). Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Annals of Oncology, 28(1), 75–82. https://doi.org/10.1093/annonc/mdw436
Inferring the Origin of Metastases from Cancer Phylogenies
Cancer Research / Sep 30, 2015
Hong, W. S., Shpak, M., & Townsend, J. P. (2015). Inferring the Origin of Metastases from Cancer Phylogenies. Cancer Research, 75(19), 4021–4025. https://doi.org/10.1158/0008-5472.can-15-1889
Radiation-Specific Clinical Data Should Be Included in Existing Large-Scale Genomic Datasets
International Journal of Radiation Oncology*Biology*Physics / May 01, 2017
Chen, W. S., Townsend, J. P., & Yu, J. B. (2017). Radiation-Specific Clinical Data Should Be Included in Existing Large-Scale Genomic Datasets. International Journal of Radiation Oncology*Biology*Physics, 98(1), 8–10. https://doi.org/10.1016/j.ijrobp.2017.01.023
Athul Prasad
5G / 6G Technology and Ventures at Samsung; D.Sc. (Tech), MBA
Most Relevant Research Interests
Other Research Interests (44)
About
Most Relevant Publications (1+)
75 total publications
A CO-ORDINATED INTERFERENCE CANCELLATION METHOD FOR MIMO FOR SELF-INTERFERENCE MITIGATION
Journal of Pharmaceutical Negative Results / Jan 01, 2022
A CO-ORDINATED INTERFERENCE CANCELLATION METHOD FOR MIMO FOR SELF-INTERFERENCE MITIGATION. (2022). Journal of Pharmaceutical Negative Results, 13(S01). https://doi.org/10.47750/pnr.2022.13.s01.64
Liam D. Hendrikse, Ph.D.
Bioinformatician at the University Health Network in Toronto, CA, specializing in computational cancer research using various sequencing modalities.
Most Relevant Research Interests
Other Research Interests (14)
About
Most Relevant Publications (4+)
10 total publications
H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone
Cancer Discovery / Dec 01, 2020
Khazaei, S., De Jay, N., Deshmukh, S., Hendrikse, L. D., Jawhar, W., Chen, C. C. L., Mikael, L. G., Faury, D., Marchione, D. M., Lanoix, J., Bonneil, É., Ishii, T., Jain, S. U., Rossokhata, K., Sihota, T. S., Eveleigh, R., Lisi, V., Harutyunyan, A. S., Jung, S., … Jabado, N. (2020). H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone. Cancer Discovery, 10(12), 1968–1987. https://doi.org/10.1158/2159-8290.cd-20-0461
MDB-07. MYC AND TGFΒ PROMOTE GROUP 3 MEDULLOBLASTOMA TUMOR RESISTANCE THROUGH DEREGULATION OF KDM2B TARGETS
Neuro-Oncology / Jun 01, 2023
Qadeer, Z., Westelman, S., Johnson, M., Grele, S., Hou, E., Hendrikse, L., Wang, L., Husain, S., Beytagh, M. C., Schmidt, C., Huang, M., Taylor, M., & Weiss, W. (2023). MDB-07. MYC AND TGFΒ PROMOTE GROUP 3 MEDULLOBLASTOMA TUMOR RESISTANCE THROUGH DEREGULATION OF KDM2B TARGETS. Neuro-Oncology, 25(Supplement_1), i62–i63. https://doi.org/10.1093/neuonc/noad073.240
MDB-21. THE OTX2-REGULATED ALTERNATIVE SPLICING LANDSCAPE CONTROLS DIFFERENTIATION AND RECONSTITUTES THE DEVELOPMENTAL ORIGINS OF GROUP 3 MEDULLOBLASTOMA
Neuro-Oncology / Jun 01, 2023
Saulnier, O., Zagozewski, J., Liang, L., Hendrikse, L. D., Gordon, V., Aldinger, K. A., Haldipur, P., Borlase, S., Coudiere-Morrison, L., Layug, P., Cai, T., Porter, C. J., Richard, S., Doble, B. W., Millen, K. J., Taylor, M. D., & Werbowetski-Ogilvie, T. E. (2023). MDB-21. THE OTX2-REGULATED ALTERNATIVE SPLICING LANDSCAPE CONTROLS DIFFERENTIATION AND RECONSTITUTES THE DEVELOPMENTAL ORIGINS OF GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 25(Supplement_1), i66–i67. https://doi.org/10.1093/neuonc/noad073.254
DDDR-33. TARGETING TGFΒ PATHWAY DEPENDENCIES IN GROUP 3 MEDULLOBLASTOMA
Neuro-Oncology / Nov 01, 2022
Qadeer, Z., Westelman, S., Johnson, M., Grele, S., Hendrikse, L., Taylor, M., & Weiss, W. (2022). DDDR-33. TARGETING TGFΒ PATHWAY DEPENDENCIES IN GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 24(Supplement_7), vii106–vii106. https://doi.org/10.1093/neuonc/noac209.398
Giuliana Noratto
Food Scientist PhD and Registered Dietician - Texas A&M University
Most Relevant Research Interests
Other Research Interests (49)
About
Most Relevant Publications (2+)
91 total publications
Dark Sweet Cherry (Prunus avium) Phenolics Enriched in Anthocyanins Induced Apoptosis in MDA-MB-453 Breast Cancer Cells through MAPK-Dependent Signaling and Reduced Invasion via Akt and PLCγ-1 Downregulation
Nutrition and Cancer / Sep 14, 2020
Layosa, M. A. A., Lage, N. N., Chew, B. P., Atienza, L., Mertens-Talcott, S., Talcott, S., & Noratto, G. D. (2020). Dark Sweet Cherry (Prunus avium) Phenolics Enriched in Anthocyanins Induced Apoptosis in MDA-MB-453 Breast Cancer Cells through MAPK-Dependent Signaling and Reduced Invasion via Akt and PLCγ-1 Downregulation. Nutrition and Cancer, 73(10), 1985–1997. https://doi.org/10.1080/01635581.2020.1817514
Pro-Apoptotic Activities of Polyphenolics From Açai (Euterpe oleraceaMartius) in Human SW-480 Colon Cancer Cells
Nutrition and Cancer / Oct 20, 2014
Dias, M. M. dos S., Noratto, G., Martino, H. S. D., Arbizu, S., Peluzio, M. do C. G., Talcott, S., Ramos, A. M., & Mertens-Talcott, S. U. (2014). Pro-Apoptotic Activities of Polyphenolics From Açai (Euterpe oleraceaMartius) in Human SW-480 Colon Cancer Cells. Nutrition and Cancer, 66(8), 1394–1405. https://doi.org/10.1080/01635581.2014.956252
Marina Baretti
I am a clinical translational researcher in gastrointestinal (GI) oncology, collaborating closely with laboratory-based researchers to move laboratory findings into patients and to answer important clinical questions.
Most Relevant Research Interests
Other Research Interests (19)
About
Most Relevant Publications (43+)
57 total publications
Neutrophil and lymphocyte blood count as potential predictive indicators of nivolumab efficacy in metastatic non-small-cell lung cancer
Immunotherapy / Jul 01, 2020
Rossi, S., Toschi, L., Finocchiaro, G., & Santoro, A. (2020). Neutrophil and lymphocyte blood count as potential predictive indicators of nivolumab efficacy in metastatic non-small-cell lung cancer. Immunotherapy, 12(10), 715–724. https://doi.org/10.2217/imt-2019-0154
The role of epigenetic therapies in colorectal cancer
Current Problems in Cancer / Nov 01, 2018
Baretti, M., & Azad, N. S. (2018). The role of epigenetic therapies in colorectal cancer. Current Problems in Cancer, 42(6), 530–547. https://doi.org/10.1016/j.currproblcancer.2018.03.001
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram
Annals of Oncology / Mar 01, 2017
Pietrantonio, F., Miceli, R., Rimassa, L., Lonardi, S., Aprile, G., Mennitto, A., Marmorino, F., Bozzarelli, S., Antonuzzo, L., Tamburini, E., Morano, F., Rossini, D., Battaglin, F., Baretti, M., Berenato, R., Formica, V., Mosconi, S., Petrelli, F., Ghidini, M., … Cremolini, C. (2017). Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. Annals of Oncology, 28(3), 555–561. https://doi.org/10.1093/annonc/mdw627
KRAS
mutation in lung metastases from
colorectal cancer: prognostic
implications
Cancer Medicine / Dec 29, 2015
Ghidini, M., Personeni, N., Bozzarelli, S., Baretti, M., Basso, G., Bianchi, P., Tronconi, M. C., Pressiani, T., Grizzi, F., Giordano, L., Malesci, A., Alloisio, M., Laghi, L., Santoro, A., & Rimassa, L. (2015). <scp>KRAS</scp> mutation in lung metastases from colorectal cancer: prognostic implications. Cancer Medicine, 5(2), 256–264. Portico. https://doi.org/10.1002/cam4.592
Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma
Immunotherapy / Dec 01, 2016
Simonelli, M., Di Tommaso, L., Baretti, M., & Santoro, A. (2016). Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma. Immunotherapy, 8(12), 1363–1369. https://doi.org/10.2217/imt-2016-0057
Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures
JCO Precision Oncology / Jun 01, 2022
Mody, K., Jain, P., El-Refai, S. M., Azad, N. S., Zabransky, D. J., Baretti, M., Shroff, R. T., Kelley, R. K., El-Khouiery, A. B., Hockenberry, A. J., Lau, D., Lesinski, G. B., & Yarchoan, M. (2022). Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures. JCO Precision Oncology, 6. https://doi.org/10.1200/po.21.00510
Targeting the epigenome of pancreatic cancer for therapy: challenges and opportunities
Annals of Pancreatic Cancer / Oct 01, 2019
Baretti, M., Ahuja, N., & Azad, N. S. (2019). Targeting the epigenome of pancreatic cancer for therapy: challenges and opportunities. Annals of Pancreatic Cancer, 2, 18–18. https://doi.org/10.21037/apc.2019.10.01
Entinostat in combination with nivolumab for patients with advanced cholangiocarcinoma and pancreatic adenocarcinoma.
Journal of Clinical Oncology / May 20, 2018
Baretti, M., Durham, J. N., Walker, R., Mitcheltree, A.-L., Christmas, B., Cope, L., Jaffee, E. M., & Azad, N. S. (2018). Entinostat in combination with nivolumab for patients with advanced cholangiocarcinoma and pancreatic adenocarcinoma. Journal of Clinical Oncology, 36(15_suppl), TPS4151–TPS4151. https://doi.org/10.1200/jco.2018.36.15_suppl.tps4151
Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic
Cancer Control / Jan 01, 2021
Jia, A. Y., Popovic, A., Mohan, A. A., Zorzi, J., Griffith, P., Kim, A. K., Anders, R. A., Burkhart, R. A., Lafaro, K., Georgiades, C., Azad, N. S., Liddell, R. P., Baretti, M., Kamel, I. R., Narang, A., Yarchoan, M., & Meyer, J. (2021). Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic. Cancer Control, 28, 107327482110099. https://doi.org/10.1177/10732748211009945
Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection
OncoImmunology / Jan 01, 2021
Delitto, D., Zabransky, D. J., Chen, F., Thompson, E. D., Zimmerman, J. W., Armstrong, T. D., Leatherman, J. M., Suri, R., Lopez-Vidal, T. Y., Huff, A. L., Lyman, M. R., Guinn, S. R., Baretti, M., Kagohara, L. T., Ho, W. J., Azad, N. S., Burns, W. R., He, J., Wolfgang, C. L., … Jaffee, E. M. (2021). Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. OncoImmunology, 10(1). https://doi.org/10.1080/2162402x.2021.2001159
Expanding the immunotherapy roadmap for hepatocellular carcinoma
Cancer Cell / Mar 01, 2022
Baretti, M., Kim, A. K., & Anders, R. A. (2022). Expanding the immunotherapy roadmap for hepatocellular carcinoma. Cancer Cell, 40(3), 252–254. https://doi.org/10.1016/j.ccell.2022.02.017
Precision Cancer Trials With Immunomodulatory Agents
The Cancer Journal / Jul 01, 2019
Baretti, M., & Azad, N. S. (2019). Precision Cancer Trials With Immunomodulatory Agents. The Cancer Journal, 25(4), 287–295. https://doi.org/10.1097/ppo.0000000000000390
Regorafenib in patients with refractory metastatic pancreatic cancer. An open-label phase II study (RESOUND)
Annals of Oncology / Oct 01, 2016
Bozzarelli, S., Rimassa, L., Giordano, L., Sala, S., Tronconi, M. C., Baretti, M., Personeni, N., Pressiani, T., & Santoro, A. (2016). Regorafenib in patients with refractory metastatic pancreatic cancer. An open-label phase II study (RESOUND). Annals of Oncology, 27, vi233. https://doi.org/10.1093/annonc/mdw371.84
Clinical Interest of Digital Pcr for Routine Detection of Circulating Dna in Metastatic Colorectal Cancer
Annals of Oncology / Sep 01, 2014
Sefrioui, D., Vasseur, C., Sesboué, R., Blanchard, F., Gangloff, A., Baretti, M., Beaussire, L., Clatot, F., Dolfus, C., Sabourin, J., Michel, P., Frebourg, T., & Di Fiore, F. (2014). Clinical Interest of Digital Pcr for Routine Detection of Circulating Dna in Metastatic Colorectal Cancer. Annals of Oncology, 25, iv559. https://doi.org/10.1093/annonc/mdu358.48
Modified Folfoxiri in advanced Pancreatic Cancer
Annals of Oncology / Sep 01, 2012
Ginocchi, L., Vasile, E., Caponi, S., Lucchesi, M., Caparello, C., Da Prat, V., Baretti, M., Lencioni, M., Ricci, S., & Falcone, A. (2012). Modified Folfoxiri in advanced Pancreatic Cancer. Annals of Oncology, 23, ix238. https://doi.org/10.1016/s0923-7534(20)33292-0
TH-302 + Gemcitabine (G + T) vs Gemcitabine (G) in Patients with Previously Untreated advanced Pancreatic Cancer (PAC)
Annals of Oncology / Sep 01, 2012
Borad, M., Reddy, S., Bahary, N., Uronis, H., Sigal, D. S., Cohn, A. L., Schelman, W., Stephenson, J., Eng, C., & Ryan, D. P. (2012). TH-302 + Gemcitabine (G + T) vs Gemcitabine (G) in Patients with Previously Untreated advanced Pancreatic Cancer (PAC). Annals of Oncology, 23, ix224. https://doi.org/10.1093/annonc/mds398
Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors
Cancers / Oct 30, 2022
Chen, K. Y., Popovic, A., Hsiehchen, D., Baretti, M., Griffith, P., Bista, R., Baghdadi, A., Kamel, I. R., Simon, S. M., Migler, R. D., & Yarchoan, M. (2022). Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers, 14(21), 5347. https://doi.org/10.3390/cancers14215347
1470P Oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence
Annals of Oncology / Sep 01, 2021
Heumann, T. R., Baretti, M., Sugar, E., Durhman, J., Liden, S., Miles, T., Lopez-Vidal, T. Y., Leatherman, J., Sharma, A., Ahuja, N., Weekes, C. D., O’Dwyer, P. J., Monga, D. K., Reiss Binder, K. A., & Azad, N. (2021). 1470P Oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Annals of Oncology, 32, S1087–S1088. https://doi.org/10.1016/j.annonc.2021.08.797
Estimating 12-weeks life expectancy in metastatic gastric cancer (mGC) patients (pts) candidates for second-line treatment: The “Gastric Life” nomogram
Annals of Oncology / Sep 01, 2017
Pietrantonio, F., Barretta, F., Fanotto, V., Niger, M., Morano, F., Bergamo, F., Silvestris, N., Fornaro, L., Bordonaro, R., Baretti, M., Santini, D., Tomasello, G., Antonuzzo, L., Noventa, S., Avallone, A., Di Donato, S., Maiello, E., De Vita, F., Miceli, R., & Aprile, G. (2017). Estimating 12-weeks life expectancy in metastatic gastric cancer (mGC) patients (pts) candidates for second-line treatment: The “Gastric Life” nomogram. Annals of Oncology, 28, v227. https://doi.org/10.1093/annonc/mdx369.052
ONC-2014-001: An open-label phase II study of regorafenib in patients with metastatic solid tumors who have progressed after standard therapy - RESOUND
Annals of Oncology / Oct 01, 2015
Bozzarelli, S., Rimassa, L., Giordano, L., Garassino, I., Marrari, A., Tronconi, M. C., De Sanctis, R. M., Cavina, R., Baretti, M., Personeni, N., Pressiani, T., & Santoro, A. (2015). ONC-2014-001: An open-label phase II study of regorafenib in patients with metastatic solid tumors who have progressed after standard therapy - RESOUND. Annals of Oncology, 26, vi150. https://doi.org/10.1093/annonc/mdv348.59
Abstract 3679: DNAJB1-PRKACA fusion in fibrolamellar hepatocellular carcinoma induces glutamine addiction and an immunosuppressive tumor microenvironment
Cancer Research / Apr 04, 2023
Kamdar, Z., Lopez-Vidal, T., Howe, K., Munjal, K., Saeed, A., Zabransky, D., Shu, D., Longway, G., Kartalia, E., Leatherman, J., Mohan, A., Khare, P., Zhang, C., Le, A., Pearce, E., Furth, M., Baretti, M., Leone, R., Jaffee, E., & Yarchoan, M. (2023). Abstract 3679: DNAJB1-PRKACA fusion in fibrolamellar hepatocellular carcinoma induces glutamine addiction and an immunosuppressive tumor microenvironment. Cancer Research, 83(7_Supplement), 3679–3679. https://doi.org/10.1158/1538-7445.am2023-3679
Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer
Oncotarget / Jul 28, 2022
Baretti, M., Zhu, Q., Fu, W., Meyer, J., Wang, H., Anders, R. A., & Azad, N. S. (2022). Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer. Oncotarget, 13(1), 907–917. https://doi.org/10.18632/oncotarget.28255
SILVELUL project: Immunohistochemical panel analyses as potential predictive and prognostic factors in pancreatic neuroendocrine tumours (PanNET) treated with CAPTEM or everolimus
Annals of Oncology / Oct 01, 2019
De Jesus-Acosta, A., Crespo Herrero, G., Gómez-Dorronsoro, M. L., Alonso, V., Riesco Martinez, M. C., Custodio, A., Lopez, C., Benavent, M., Carmona Bayonas, A., Jimenez-Fonseca, P., Llanos, M., López De San Vicente, B., Arrazubi Arrula, V., Grandez, R., González-Borja, I., Goñi, S., Arozarena, I., Baretti, M., & Viudez, A. (2019). SILVELUL project: Immunohistochemical panel analyses as potential predictive and prognostic factors in pancreatic neuroendocrine tumours (PanNET) treated with CAPTEM or everolimus. Annals of Oncology, 30, v196. https://doi.org/10.1093/annonc/mdz245.006
Chemoradiation-induced alteration of programmed death-ligand 1 and CD8+ tumor-infiltrating lymphocytes in rectal cancer.
Journal of Clinical Oncology / Feb 01, 2019
Baretti, M., Fu, W., Wang, H., Anders, R. A., Azad, N. S., & Zhu, Q. (2019). Chemoradiation-induced alteration of programmed death-ligand 1 and CD8+ tumor-infiltrating lymphocytes in rectal cancer. Journal of Clinical Oncology, 37(4_suppl), 570–570. https://doi.org/10.1200/jco.2019.37.4_suppl.570
The impact of the immune microenvironment in patients with GEP-NETs.
Journal of Clinical Oncology / Feb 01, 2019
Baretti, M., Zhu, Q., Zahurak, M., Pawlik, T. M., Anders, R. A., & De Jesus-Acosta, A. (2019). The impact of the immune microenvironment in patients with GEP-NETs. Journal of Clinical Oncology, 37(4_suppl), 267–267. https://doi.org/10.1200/jco.2019.37.4_suppl.267
Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram
Annals of Oncology / Oct 01, 2017
Morano, F., Pietrantonio, F., Barretta, F., Fanotto, V., Niger, M., Nichetti, F., Bergamo, F., Silvestris, N., Fornaro, L., Bordonaro, R., Baretti, M., Santini, D., Tomasello, G., Antonuzzo, L., Noventa, S., Avallone, A., Di Donato, S., Maiello, E., De Vita, F., & Aprile, G. (2017). Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram. Annals of Oncology, 28, vi46–vi47. https://doi.org/10.1093/annonc/mdx425.008
Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram
Annals of Oncology / Oct 01, 2017
Morano, F., Pietrantonio, F., Barretta, F., Fanotto, V., Niger, M., Nichetti, F., Bergamo, F., Silvestris, N., Fornaro, L., Bordonaro, R., Baretti, M., Santini, D., Tomasello, G., Antonuzzo, L., Noventa, S., Avallone, A., Di Donato, S., Maiello, E., De Vita, F., & Aprile, G. (2017). Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram. Annals of Oncology, 28, vi46–vi47. https://doi.org/10.1093/annonc/mdx425.008
P1.07-018 Incidence of Brain Recurrence and Survival Outcomes in High-Grade Neuroendocrine Carcinomas of the Lung: Implications for Clinical Practice
Journal of Thoracic Oncology / Jan 01, 2017
Mountzios, G., Ricciuti, B., Chiari, R., Baretti, M., Falcinelli, L., Giannarelli, D., Sidoni, A., Crinò, L., Bellezza, G., Rebonato, A., Ferolla, P., Toschi, L., & Metro, G. (2017). P1.07-018 Incidence of Brain Recurrence and Survival Outcomes in High-Grade Neuroendocrine Carcinomas of the Lung: Implications for Clinical Practice. Journal of Thoracic Oncology, 12(1), S706–S707. https://doi.org/10.1016/j.jtho.2016.11.930
Evaluation of Charlson comorbidity index as predictor of survival in stage II-III colorectal cancer patients treated with surgery and neoadjuvant/adjuvant chemotherapy: A single Institution observational study
Annals of Oncology / Oct 01, 2016
Baretti, M., Personeni, N., Giordano, L., Tronconi, M. C., Pressiani, T., Bozzarelli, S., Rimassa, L., & Santoro, A. (2016). Evaluation of Charlson comorbidity index as predictor of survival in stage II-III colorectal cancer patients treated with surgery and neoadjuvant/adjuvant chemotherapy: A single Institution observational study. Annals of Oncology, 27, vi183. https://doi.org/10.1093/annonc/mdw370.104
Prognostic impact of comorbidity in stage II-III colorectal cancer (CRC) patients treated with surgery and neoadjuvant/adjuvant chemotherapy: a single Institution observational study
Annals of Oncology / Sep 01, 2016
Baretti, M., Giordano, L., Rimassa, L., Tronconi, M. C., Pressiani, T., Bozzarelli, S., Personeni, N., & Santoro, A. (2016). Prognostic impact of comorbidity in stage II-III colorectal cancer (CRC) patients treated with surgery and neoadjuvant/adjuvant chemotherapy: a single Institution observational study. Annals of Oncology, 27, iv48. https://doi.org/10.1093/annonc/mdw335.29
An open-label phase II study (RESOUND) of Regorafenib in patients with refractory solid tumors. Results of pancreatic cohort
Annals of Oncology / Sep 01, 2016
Bozzarelli, S., Rimassa, L., Giordano, L., Sala, S., Tronconi, M. C., Baretti, M., Personeni, N., Pressiani, T., & Santoro, A. (2016). An open-label phase II study (RESOUND) of Regorafenib in patients with refractory solid tumors. Results of pancreatic cohort. Annals of Oncology, 27, iv25. https://doi.org/10.1093/annonc/mdw333.29
Palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer: a large Italian experience
Annals of Oncology / Sep 01, 2016
Fanotto, V., Fontanella, C., Cordio, S., Pasquini, G., Baretti, M., Filippi, R., Rosati, G., Santini, D., Giampieri, R., Di Donato, S., Tomasello, G., Brunetti, O., Caporale, M., Bergamo, F., Avallone, A., Scartozzi, M., Lutrino, E. S., Melisi, D., Antonuzzo, L., … Aprile, G. (2016). Palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer: a large Italian experience. Annals of Oncology, 27, iv18. https://doi.org/10.1093/annonc/mdw333.03
P-173 Outcomes of palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer
Annals of Oncology / Jun 01, 2016
Fanotto, V., Fontanella, C., Cordio, S., Pasquini, G., Baretti, M., Filippi, R., Rosati, G., Santini, D., Giampieri, R., Di Donato, S., Tomasello, G., Brunetti, O., Caporale, M., Bergamo, F., Avallone, A., Scartozzi, M., Lutrino, S., Melisi, D., Antonuzzo, L., … Aprile, G. (2016). P-173 Outcomes of palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer. Annals of Oncology, 27, ii51. https://doi.org/10.1093/annonc/mdw199.167
O-013 A new nomogram for estimating 12-weeks survival in patients (pts) with chemorefractory metastatic colorectal cancer (mCRC)
Annals of Oncology / Jun 01, 2016
Pietrantonio, F., Cremolini, C., Rimassa, L., Lonardi, S., Mennitto, A., Morano, F., Iacono, D., Berenato, R., Caporale, M., Niger, M., Marmorino, F., Bozzarelli, S., Bergamo, F., Rossini, D., Baretti, M., Battaglin, F., Bonotto, M., Loupakis, F., de Braud, F., & Miceli, R. (2016). O-013 A new nomogram for estimating 12-weeks survival in patients (pts) with chemorefractory metastatic colorectal cancer (mCRC). Annals of Oncology, 27, ii122. https://doi.org/10.1093/annonc/mdw198.13
Third-Line Folfiri in Metastatic Gastric Cancer Patients
Annals of Oncology / Sep 01, 2012
Caparello, C., Vasile, E., Lencioni, M., Fabrini, M. G., Lucchesi, M., Ginocchi, L., Caponi, S., Santi, S., Ricci, S., & Falcone, A. (2012). Third-Line Folfiri in Metastatic Gastric Cancer Patients. Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33344-5
Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC)
Annals of Oncology / Sep 01, 2012
Caparello, C., Lencioni, M., Vasile, E., Caponi, S., Santi, S., Fabrini, M. G., Ginocchi, L., Lucchesi, M., Ricci, S., & Falcone, A. (2012). Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC). Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33343-3
Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC)
Annals of Oncology / Sep 01, 2012
Caparello, C., Lencioni, M., Vasile, E., Caponi, S., Santi, S., Fabrini, M. G., Ginocchi, L., Lucchesi, M., Ricci, S., & Falcone, A. (2012). Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC). Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33343-3
Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC)
Annals of Oncology / Sep 01, 2012
Caparello, C., Lencioni, M., Vasile, E., Caponi, S., Santi, S., Fabrini, M. G., Ginocchi, L., Lucchesi, M., Ricci, S., & Falcone, A. (2012). Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC). Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33343-3
Evaluation of prognostic factors and of the role of adjuvant chemotherapy in patients with invasive carcinoma derived from intraductal papillary mucinous neoplasms (IPMNs) of the pancreas.
Journal of Clinical Oncology / May 20, 2010
Vasile, E., Caponi, S., Lucchesi, M., Del Chiaro, M., Funel, N., Ginocchi, L., Campani, D., Falcone, A., Boggi, U., & Mosca, F. (2010). Evaluation of prognostic factors and of the role of adjuvant chemotherapy in patients with invasive carcinoma derived from intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. Journal of Clinical Oncology, 28(15_suppl), e14605–e14605. https://doi.org/10.1200/jco.2010.28.15_suppl.e14605
Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study
Clinical Colorectal Cancer / Sep 01, 2018
Baretti, M., Rimassa, L., Personeni, N., Giordano, L., Tronconi, M. C., Pressiani, T., Bozzarelli, S., & Santoro, A. (2018). Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study. Clinical Colorectal Cancer, 17(3), e489–e498. https://doi.org/10.1016/j.clcc.2018.03.010
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity?
Cancer Biology & Therapy / Apr 13, 2018
Baretti, M., Personeni, N., Destro, A., Santoro, A., & Rimassa, L. (2018). Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity? Cancer Biology & Therapy, 19(8), 659–663. https://doi.org/10.1080/15384047.2018.1450117
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications
Gastric Cancer / Aug 16, 2016
Personeni, N., Baretti, M., Bozzarelli, S., Spaggiari, P., Rubino, L., Tronconi, M. C., Fumagalli Romario, U., Rosati, R., Giordano, L., Roncalli, M., Santoro, A., & Rimassa, L. (2016). Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications. Gastric Cancer, 20(3), 428–437. https://doi.org/10.1007/s10120-016-0625-1
Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice
Lung Cancer / May 01, 2016
Metro, G., Ricciuti, B., Chiari, R., Baretti, M., Falcinelli, L., Giannarelli, D., Sidoni, A., Mountzios, G., Crinò, L., Bellezza, G., Rebonato, A., Ferolla, P., & Toschi, L. (2016). Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice. Lung Cancer, 95, 82–87. https://doi.org/10.1016/j.lungcan.2016.03.006
Ramy Ayoub
Ph.D. Candidate, University of Toronto | SickKids Hospital
Most Relevant Research Interests
Other Research Interests (15)
About
Most Relevant Publications (1+)
7 total publications
QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY
Neuro-Oncology / Jun 01, 2018
Ayoub, R., Miller, F., Beera, K., de Medeiros, C., Laughlin, S., Bouffet, E., & Mabbott, D. (2018). QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY. Neuro-Oncology, 20(suppl_2), i168–i168. https://doi.org/10.1093/neuonc/noy059.634
Timothy Sears
PhD student, Bioinformatics, UC San Diego
Most Relevant Research Interests
Other Research Interests (14)
About
Most Relevant Publications (3+)
7 total publications
Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
Clinical Cancer Research / May 02, 2023
Bui, N. Q., Nemat-Gorgani, N., Subramanian, A., Torres, I. A., Lohman, M., Sears, T. J., van de Rijn, M., Charville, G. W., Becker, H.-C., Wang, D. S., Hwang, G. L., Ganjoo, K. N., & Moding, E. J. (2023). Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis. Clinical Cancer Research, 29(14), 2612–2620. https://doi.org/10.1158/1078-0432.ccr-23-0250
Abstract 5960: Identification and validation of sarcoma cellular ecosystems associated with prognosis and predictive of immunotherapy response
Cancer Research / Apr 04, 2023
Subramanian, A., Nemat-Gorgani, N., Ellis-Caleo, T. J., van IJzendoorn, D. G. P., Sears, T. J., Somani, A., Luca, B. A., Zhou, M. Y., Bradic, M., Torres, I. A., Oladipo, E., New, C., Kenney, D. E., Avedian, R. S., Steffner, R. J., Binkley, M. S., Mohler, D. G., Tap, W. D., D’Angelo, S. P., … Moding, E. J. (2023). Abstract 5960: Identification and validation of sarcoma cellular ecosystems associated with prognosis and predictive of immunotherapy response. Cancer Research, 83(7_Supplement), 5960–5960. https://doi.org/10.1158/1538-7445.am2023-5960
Abstract 3825: Germline modifiers of the tumor immune microenvironment reveal drivers of immunotherapy response
Cancer Research / Jun 15, 2022
Pagadala, M., Wu, V., Pérez-Guijarro, E., Kim, H., Castro, A., Talwar, J., Gonzalez-Colin, C., Cao, S., Schmiedel, B. J., Sears, T., Goudarzi, S., Kirani, D., Salem, R. M., Morris, G. P., Harismendy, O., Patel, S. P., Mesirov, J. P., Zanetti, M., Day, C.-P., … Carter, H. (2022). Abstract 3825: Germline modifiers of the tumor immune microenvironment reveal drivers of immunotherapy response. Cancer Research, 82(12_Supplement), 3825–3825. https://doi.org/10.1158/1538-7445.am2022-3825
Katelyn Katelyn Masiuk
Co-Founder and CSO at Immunovec
Most Relevant Research Interests
Other Research Interests (25)
About
Most Relevant Publications (1+)
13 total publications
Pharmacologic Inhibition of ALK5 Causes Selective Induction of Terminal Differentiation in Mouse Keratinocytes Expressing Oncogenic HRAS
Molecular Cancer Research / Jun 01, 2011
Markell, L. M., Masiuk, K. E., Blazanin, N., & Glick, A. B. (2011). Pharmacologic Inhibition of ALK5 Causes Selective Induction of Terminal Differentiation in Mouse Keratinocytes Expressing Oncogenic HRAS. Molecular Cancer Research, 9(6), 746–756. https://doi.org/10.1158/1541-7786.mcr-11-0112
Kayvan Najarian
Professor of Comp Med and Bioinf, Emergency Med, and Electrical and Comp Engineering
Most Relevant Research Interests
Other Research Interests (40)
Most Relevant Publications (1+)
108 total publications
Signatures of tumor–immune interactions as biomarkers for breast cancer prognosis
Future Oncology / Jun 01, 2012
Manjili, M. H., Najarian, K., & Wang, X.-Y. (2012). Signatures of tumor–immune interactions as biomarkers for breast cancer prognosis. Future Oncology, 8(6), 703–711. https://doi.org/10.2217/fon.12.57
Amir Manbachi
Co-director and Founder of the Johns Hopkins HEPIUS Innovation Lab
Most Relevant Research Interests
Other Research Interests (56)
Most Relevant Publications (3+)
92 total publications
Reusable Core Needle Biopsy Device for Low-Resource Settings
Journal of Global Oncology / Oct 01, 2018
Callanan, M., Zawicki, V., Hinson, L., Lee, M., Triantis, S., Manbachi, A., & Harvey, S. (2018). Reusable Core Needle Biopsy Device for Low-Resource Settings. Journal of Global Oncology, 4(Supplement 3), 47s–47s. https://doi.org/10.1200/jgo.18.10550
Towards standardization of the parameters for opening the blood–brain barrier with focused ultrasound to treat glioblastoma multiforme: A systematic review of the devices, animal models, and therapeutic compounds used in rodent tumor models
Frontiers in Oncology / Feb 16, 2023
Thombre, R., Mess, G., Kempski Leadingham, K. M., Kapoor, S., Hersh, A., Acord, M., Kaovasia, T., Theodore, N., Tyler, B., & Manbachi, A. (2023). Towards standardization of the parameters for opening the blood–brain barrier with focused ultrasound to treat glioblastoma multiforme: A systematic review of the devices, animal models, and therapeutic compounds used in rodent tumor models. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.1072780
Applications of Focused Ultrasound for the Treatment of Glioblastoma: A New Frontier
Cancers / Oct 08, 2022
Hersh, A. M., Bhimreddy, M., Weber-Levine, C., Jiang, K., Alomari, S., Theodore, N., Manbachi, A., & Tyler, B. M. (2022). Applications of Focused Ultrasound for the Treatment of Glioblastoma: A New Frontier. Cancers, 14(19), 4920. https://doi.org/10.3390/cancers14194920
Jens Hegg
Professor studying chemicalAnd isotopic records in animal hard parts.
Most Relevant Research Interests
Other Research Interests (18)
Most Relevant Publications (1+)
20 total publications
Ratcheting Myc
Cancer Cell / Dec 01, 2008
Freie, B. W., & Eisenman, R. N. (2008). Ratcheting Myc. Cancer Cell, 14(6), 425–426. https://doi.org/10.1016/j.ccr.2008.11.008
Olivier Saulnier
The Hospital for Sick Children
Most Relevant Research Interests
Other Research Interests (17)
Most Relevant Publications (6+)
25 total publications
EPEN-52. METABOLIC REGULATION OF THE EPIGENOME DRIVES LETHAL INFANTILE EPENDYMOMA
Neuro-Oncology / Dec 01, 2020
Kumar, S., Michealraj, A., Kim, L., Rich, J., & Taylor, M. (2020). EPEN-52. METABOLIC REGULATION OF THE EPIGENOME DRIVES LETHAL INFANTILE EPENDYMOMA. Neuro-Oncology, 22(Supplement_3), iii318–iii318. https://doi.org/10.1093/neuonc/noaa222.185
MDB-21. THE OTX2-REGULATED ALTERNATIVE SPLICING LANDSCAPE CONTROLS DIFFERENTIATION AND RECONSTITUTES THE DEVELOPMENTAL ORIGINS OF GROUP 3 MEDULLOBLASTOMA
Neuro-Oncology / Jun 01, 2023
Saulnier, O., Zagozewski, J., Liang, L., Hendrikse, L. D., Gordon, V., Aldinger, K. A., Haldipur, P., Borlase, S., Coudiere-Morrison, L., Layug, P., Cai, T., Porter, C. J., Richard, S., Doble, B. W., Millen, K. J., Taylor, M. D., & Werbowetski-Ogilvie, T. E. (2023). MDB-21. THE OTX2-REGULATED ALTERNATIVE SPLICING LANDSCAPE CONTROLS DIFFERENTIATION AND RECONSTITUTES THE DEVELOPMENTAL ORIGINS OF GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 25(Supplement_1), i66–i67. https://doi.org/10.1093/neuonc/noad073.254
BIOL-23. LOSS OF MICRORNAS COOPERATES WITH TUMOR SUPPRESSORS TO INITIATE MYC-DEPENDENT METASTATIC MEDULLOBLASTOMA
Neuro-Oncology / Jun 01, 2023
Llaguno, S. A., Nazarenko, I., Chen, Y., Sun, D., Gudenas, B., Saulnier, O., Rocca, G. L., Pedraza, A., Burns, D., Bale, T., Ventura, A., Northcott, P., Taylor, M., & Parada, L. (2023). BIOL-23. LOSS OF MICRORNAS COOPERATES WITH TUMOR SUPPRESSORS TO INITIATE MYC-DEPENDENT METASTATIC MEDULLOBLASTOMA. Neuro-Oncology, 25(Supplement_1), i11–i11. https://doi.org/10.1093/neuonc/noad073.042
Abstract IA009: Oncogenic transcription factors drive highly tumor-specific LincRNA
Clinical Cancer Research / Sep 15, 2022
Delattre, O., Vibert, J., Saulnier, O., & Waterfall, J. (2022). Abstract IA009: Oncogenic transcription factors drive highly tumor-specific LincRNA. Clinical Cancer Research, 28(18_Supplement), IA009–IA009. https://doi.org/10.1158/1557-3265.sarcomas22-ia009
The LIN28B –let‐7–PBK
pathway is essential for group 3
medulloblastoma tumor growth and
survival
Molecular Oncology / Aug 07, 2023
Shahab, S. W., Roggeveen, C. M., Sun, J., Kunhiraman, H., McSwain, L. F., Juraschka, K., Kumar, S. A., Saulnier, O., Taylor, M. D., Schniederjan, M., Schnepp, R. W., MacDonald, T. J., & Kenney, A. M. (2023). The <scp>LIN28B</scp>–let‐7–<scp>PBK</scp> pathway is essential for group 3 medulloblastoma tumor growth and survival. Molecular Oncology. Portico. https://doi.org/10.1002/1878-0261.13477
Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Cancer Discovery / Jan 17, 2023
Ye, Z., Ai, X., Yang, K., Yang, Z., Fei, F., Liao, X., Qiu, Z., Gimple, R. C., Yuan, H., Huang, H., Gong, Y., Xiao, C., Yue, J., Huang, L., Saulnier, O., Wang, W., Zhang, P., Dai, L., Wang, X., … Zhou, S. (2023). Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma. Cancer Discovery, 13(4), 974–1001. https://doi.org/10.1158/2159-8290.cd-22-0455
AMAN SHARMA
Postdoctoral Research Fellow, Memorial Sloan Kettering Cancer Center.
Most Relevant Research Interests
Other Research Interests (11)
Most Relevant Publications (4+)
8 total publications
Inter-Individual Variation in Response to Estrogen in Human Breast Explants
Journal of Mammary Gland Biology and Neoplasia / Mar 01, 2020
Dunphy, K. A., Black, A. L., Roberts, A. L., Sharma, A., Li, Z., Suresh, S., Browne, E. P., Arcaro, K. F., Ser-Dolansky, J., Bigelow, C., Troester, M. A., Schneider, S. S., Makari-Judson, G., Crisi, G. M., & Jerry, D. J. (2020). Inter-Individual Variation in Response to Estrogen in Human Breast Explants. Journal of Mammary Gland Biology and Neoplasia, 25(1), 51–68. https://doi.org/10.1007/s10911-020-09446-3
Genetic modifiers of p53: opportunities for breast cancer therapies
Oncotarget / Jan 12, 2023
Majhi, P. D., Sharma, A., & Jerry, D. J. (2023). Genetic modifiers of p53: opportunities for breast cancer therapies. Oncotarget, 14(1), 236–241. https://doi.org/10.18632/oncotarget.28387
Abstract P1-07-10: Estrogen-stimulated DNA damage in mammary epithelium varies among strains of rodents and women
Cancer Research / Feb 15, 2022
Dunphy, K. A., Sharma, A., Majhi, P., Schneider, S. S., Crisi, G. M., Makari-Judson, G., & Jerry, D. J. (2022). Abstract P1-07-10: Estrogen-stimulated DNA damage in mammary epithelium varies among strains of rodents and women. Cancer Research, 82(4_Supplement), P1-07-10-P1-07–10. https://doi.org/10.1158/1538-7445.sabcs21-p1-07-10
Abstract 3750: Xenoestrogens cause estrogen receptor-dependent R-loop formation and DNA damage
Cancer Research / Jul 01, 2018
Dunphy, K. A., Majhi, P. D., Sharma, A., Roberts, A. L., Daniele, E. A., Schneider, S. S., & Jerry, D. J. (2018). Abstract 3750: Xenoestrogens cause estrogen receptor-dependent R-loop formation and DNA damage. Cancer Research, 78(13_Supplement), 3750–3750. https://doi.org/10.1158/1538-7445.am2018-3750
Mehrdad Sheikhvatan
Iran University of Medical Sciences
Most Relevant Research Interests
Other Research Interests (58)
Most Relevant Publications (1+)
90 total publications
Comparison of the efficacy of intravenous tranexamic acid with and without topical administration versus placebo in urgent endoscopy rate for acute gastrointestinal bleeding: A double-blind randomized controlled trial
United European Gastroenterology Journal / Jun 20, 2017
Tavakoli, N., Mokhtare, M., Agah, S., Azizi, A., Masoodi, M., Amiri, H., Sheikhvatan, M., Syedsalehi, B., Behnam, B., Arabahmadi, M., & Mehrazi, M. (2017). Comparison of the efficacy of intravenous tranexamic acid with and without topical administration versus placebo in urgent endoscopy rate for acute gastrointestinal bleeding: A double-blind randomized controlled trial. United European Gastroenterology Journal, 6(1), 46–54. https://doi.org/10.1177/2050640617714940
Example oncology projects
How can companies collaborate more effectively with researchers, experts, and thought leaders to make progress on oncology?
Development of Targeted Cancer Therapies
An Oncology expert can collaborate with a pharmaceutical company to develop targeted therapies that specifically attack cancer cells, minimizing side effects and improving patient outcomes.
Identification of Biomarkers for Early Cancer Detection
Working with an Oncology researcher, a diagnostic company can identify biomarkers that indicate the presence of cancer at an early stage, enabling early detection and intervention.
Improving Radiation Therapy Techniques
Collaborating with an Oncology expert, a medical device company can enhance radiation therapy techniques, improving precision and minimizing damage to healthy tissues.
Development of Personalized Treatment Plans
An Oncology researcher can assist a healthcare provider in developing personalized treatment plans for cancer patients, considering individual characteristics and genetic profiles.
Exploring Immunotherapy Approaches
Working with an Oncology expert, a biotech company can explore novel immunotherapy approaches for cancer treatment, harnessing the power of the immune system to fight cancer cells.